EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: GENETIC INSIGHTS INTO ACQUIRED RESISTANCE AND CLONAL EVOLUTION IN VEN-BASED THERAPY FOR AML

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: GENETIC INSIGHTS INTO ACQUIRED RESISTANCE AND CLONAL EVOLUTION IN VEN-BASED THERAPY FOR AML

EHA Highlights 2024 Roundtable Discussions
Pre-Video Survey
Post-Video Survey
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Panelists

Dr. Julie Bergeron
Dr. Aniket Bankar

This program has been made possible through unrestricted support from Astellas.

Studies/trials discussed:

  • GENETIC INSIGHTS INTO ACQUIRED RESISTANCE AND CLONALEVOLUTION IN VENETOCLAX (VEN)-BASED THERAPY FOR ACUTE MYELOIDLEUKEMIA (AML
  • Venetoclax-based therapies for acute myeloid leukemia
Tagged